StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.06 (+3.75%)

Close on Nov 17, 2026Market cap $4.22MP/E –Yield –

Alaunos Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Alaunos Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.65M. For fiscal 2025 it was $1.36M, up 276.5% from the year before. Over ten years it grew -35.3% a year on average. The highest annual figure on record is $157.79M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.36M+276.5%
FY2024Dec 31, 2024$362.00K-97.8%
FY2023Dec 31, 2023$16.28M-34.9%
FY2022Dec 31, 2022$25.02M-49.6%
FY2021Dec 31, 2021$49.64M-5.8%
FY2020Dec 31, 2020$52.70M+37.5%
FY2019Dec 31, 2019$38.33M+12.3%
FY2018Dec 31, 2018$34.13M-24.3%
FY2017Dec 31, 2017$45.08M-71.4%
FY2016Dec 31, 2016$157.79M+47.8%
FY2015Dec 31, 2015$106.79M+226.5%
FY2014Dec 31, 2014$32.71M-23.7%
FY2013Dec 31, 2013$42.85M-48.6%
FY2012Dec 31, 2012$83.45M+46.2%
FY2011Dec 31, 2011$57.08M+342.2%
FY2010Dec 31, 2010$12.91M+183.4%
FY2009Dec 31, 2009$4.56M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$388.00K+109.7%
Q1 FY2026Mar 31, 2026$427.00K+23.1%
Q4 FY2025Dec 31, 2025$361.00K+152.4%
Q3 FY2025Sep 30, 2025$469.00K+160.6%
Q2 FY2025Jun 30, 2025$185.00K+46.8%
Q1 FY2025Mar 31, 2025$347.00K-62.8%
Q3 FY2024Sep 30, 2024$143.00K-96.1%
Q2 FY2024Jun 30, 2024$180.00K-96.5%
Q1 FY2024Mar 31, 2024$126.00K-98.1%
Q4 FY2023Dec 31, 2023$933.00K-83.4%
Q3 FY2023Sep 30, 2023$3.66M-53.7%
Q2 FY2023Jun 30, 2023$5.19M-12.6%
Q1 FY2023Mar 31, 2023$6.50M+16.6%
Q4 FY2022Dec 31, 2022$5.61M-31.8%
Q3 FY2022Sep 30, 2022$7.89M-70.7%
Q2 FY2022Jun 30, 2022$5.94M-57.5%
Q1 FY2022Mar 31, 2022$5.58M-60.1%
Q4 FY2021Dec 31, 2021$8.22M-31.8%
Q1 FY2021Jun 30, 2021$26.91M+111.8%
Q4 FY2020Dec 31, 2020$13.97M+36.8%
Q3 FY2020Sep 30, 2020$13.97M+61.6%
Q2 FY2020Jun 30, 2020$12.05M+20.5%
Q1 FY2020Mar 31, 2020$12.71M+34.1%
Q4 FY2019Dec 31, 2019$10.22M+24.6%
Q3 FY2019Sep 30, 2019$8.64M+4.6%
Q2 FY2019Jun 30, 2019$10.00M+33.5%
Q1 FY2019Mar 31, 2019$9.48M-6.9%
Q4 FY2018Dec 31, 2018$8.20M-26.7%
Q3 FY2018Sep 30, 2018$8.26M-25.6%
Q2 FY2018Jun 30, 2018$7.49M-30.9%
Q1 FY2018Mar 31, 2018$10.18M-14.9%
Q4 FY2017Dec 31, 2017$11.18M+19.1%
Q3 FY2017Sep 30, 2017$11.11M+23.7%
Q2 FY2017Jun 30, 2017$10.83M-91.6%
Q1 FY2017Mar 31, 2017$11.97M–
Q4 FY2016Dec 31, 2016$9.39M–
Q3 FY2016Sep 30, 2016$8.98M–
Q2 FY2016Jun 30, 2016$129.23M–

More Alaunos Therapeutics figures

See a number that looks wrong?